Clinical Trials Logo

Advanced NSCLC clinical trials

View clinical trials related to Advanced NSCLC.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04043195 Active, not recruiting - Advanced NSCLC Clinical Trials

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

NSCLC
Start date: August 14, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system). Nivolumab (Opdivo®) is approved by the Food and Drug Administration (FDA) for the treatment of metastatic (the cancer has spread) NSCLC. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies bind to other proteins, such as PD-1 (programmed cell death-1), on immune cells, which allows the immune cells to continue working against the tumor. Ipilumumab (Yervoy®) is also a monoclonal antibody, but binds to a protein called CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). Oxaliplatin is a type of immunogenic chemotherapy, which may increase the body's immune response to the cancer. Both are approved for treatment of other types of cancers, but not in patients with NSCLC.

NCT ID: NCT03127449 Active, not recruiting - Advanced NSCLC Clinical Trials

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).